Fox Chase Cancer Center News

Make Way for 2016: Start Taking Steps to Help Reduce Your Cancer Risk

PHILADELPHIA (December 18, 2015) – With 2016 fast approaching, Fox Chase Cancer Center – Temple Health encourage all individuals to start taking steps that could help reduce their risk for cancer. According to the American Cancer Society (ACS), more than one million Americans are diagnosed with cancer every year. Fortunately, individuals can help to prevent cancer by making healthy lifestyle choices and getting regular recommended cancer screenings. Consider these tips:

VIEW STORY

Understanding How Protein Kinases Activate Themselves Could Spawn New Anticancer Therapies

PHILADELPHIA (December 15, 2015) – Protein kinases play important roles in a range of cellular processes and have been implicated in diverse diseases, from cancer to obesity. Most of these proteins regulate their own activity through a biochemical process called autophosphorylation. Capturing snapshots of this event as it unfolds could be the key to understanding the molecular origins of disease and to developing a new generation of therapies.

VIEW STORY

Universal Hospital signs MOU with Fox Chase Cancer Center—Temple Health for BMT program in Abu Dhabi

PHILADELPHIA/ABU DHABI – (December 10, 2015) – Universal Hospital, one of Abu Dhabi’s leading health care providers, has signed a memorandum of understanding with Philadelphia-based Fox Chase Cancer Center—Temple Health to discuss establishing a world-class cancer center in the United Arab Emirates. The proposed plan would initially establish a bone marrow transplant (BMT) program followed by the first comprehensive cancer center in the private sector in the United Arab Emirates.

VIEW STORY

Combination Treatment with Decitabine Yields Higher Response for Patients with AML or MDS

PHILADELPHIA (December 7, 2015) – The combination of an epigenetic agent with arsenic trioxide may be a potential treatment for patients diagnosed with advanced myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who cannot undergo intense chemotherapy. Fox Chase Cancer Center – Temple Health researchers presented the results of a phase 2 trial at the 2015 American Society of Hematology Annual Meeting in December 2015.

VIEW STORY